Notable Price Action: Is Alexion Pharmaceuticals, Inc. a Buy? The Stock Rises Again

Notable Price Action: Is Alexion Pharmaceuticals, Inc. a Buy? The Stock Rises Again

The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a huge mover today! The stock increased 5.20% or $6.21 during the last trading session, hitting $125.59. About 3.21 million shares traded hands or 8.81% up from the average. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 22.49% since April 26, 2016 and is downtrending. It has underperformed by 27.75% the S&P500.
The move comes after 7 months positive chart setup for the $28.29 billion company. It was reported on Nov, 29 by Barchart.com. We have $131.87 PT which if reached, will make NASDAQ:ALXN worth $1.41B more.

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on February, 1. They expect $1.10 EPS, up 30.95% or $0.26 from last year’s $0.84 per share. ALXN’s profit will be $247.78M for 28.54 P/E if the $1.10 EPS becomes a reality. After $1.18 actual EPS reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -6.78% negative EPS growth.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Out of 20 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 15 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 75% are positive. Alexion Pharmaceuticals Inc. has been the topic of 40 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Equal Weight” rating by Barclays Capital on Monday, September 14. The company was upgraded on Friday, October 2 by Morgan Stanley. As per Friday, July 29, the company rating was maintained by Barclays Capital. As per Friday, October 28, the company rating was upgraded by FBR Capital. UBS maintained the stock with “Buy” rating in Thursday, February 4 report. The firm earned “Equal-Weight” rating on Thursday, February 4 by Barclays Capital. As per Friday, September 23, the company rating was maintained by Jefferies. The rating was maintained by Brean Capital on Friday, July 31 with “Buy”. On Wednesday, August 12 the stock rating was upgraded by Vetr to “Buy”. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Buy” rating given on Tuesday, September 20 by Citigroup.

According to Zacks Investment Research, “Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company’s lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.”

Insitutional Activity: The institutional sentiment decreased to 1.07 in 2016 Q2. Its down 0.12, from 1.19 in 2016Q1. The ratio fall, as 51 funds sold all Alexion Pharmaceuticals, Inc. shares owned while 155 reduced positions. 58 funds bought stakes while 188 increased positions. They now own 212.84 million shares or 4.67% less from 223.26 million shares in 2016Q1.
Exxonmobil Inc Tx has 0.14% invested in the company for 57,988 shares. Numeric Limited Liability Company last reported 2,400 shares in the company. Intrust National Bank Na, a Kansas-based fund reported 2,530 shares. Beacon Trust, a New Jersey-based fund reported 21,786 shares. Millennium Management Limited Com has 0.25% invested in the company for 918,944 shares. Mitsubishi Ufj Tru & Corporation owns 453,263 shares or 0.12% of their US portfolio. Ngam Advsr Lp has invested 0.02% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Diam Limited holds 0.2% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 117,247 shares. Ftb Advsr holds 0% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 306 shares. Ww Asset Management Inc has invested 0.1% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Lockheed Martin Inv Mgmt has invested 0.23% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Trexquant Investment Limited Partnership has invested 0.3% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Wall Street has 0.09% invested in the company for 2,000 shares. Jefferies Grp Limited Com holds 0.02% or 34,441 shares in its portfolio. Conning accumulated 0.03% or 5,390 shares.

Insider Transactions: Since June 13, 2016, the stock had 0 buys, and 19 insider sales for $9.39 million net activity. 1,000 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares with value of $125,940 were sold by Thiel Carsten. 165 shares were sold by Carmichael Clare, worth $22,628 on Monday, August 8. Hallal David had sold 332 shares worth $45,530 on Monday, August 8. $14,689 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by Wagner Heidi L on Monday, October 3. Moriarty John B also sold $124,591 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares. Miller Edward sold $47,093 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Friday, September 9. BELL LEONARD sold $5.24 million worth of stock or 37,317 shares.

More important recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Businesswire.com which released: “Robbins Arroyo LLP: Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders …” on November 22, 2016, also Schaeffersresearch.com published article titled: “Analyst Update: Mallinckrodt PLC, Alexion Pharmaceuticals, Inc., and Vascular …”, Marketwatch.com published: “Alexion Pharma shares halted, company to delay quarterly results” on November 09, 2016. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was released by: Prnewswire.com and their article: “Harwood Feffer LLP Announces Investigation of Alexion Pharmaceuticals, Inc.” with publication date: November 10, 2016.

ALXN Company Profile

Alexion Pharmaceuticals, Inc., incorporated on January 28, 1992, is a biopharmaceutical company. The Firm is focused on the development and commercialization of life-transforming therapeutic products. The Firm operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment